Virus therapy plus immunotherapy for advanced mesothelioma
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if injecting a cancer-killing virus directly into tumors, combined with an immunotherapy drug, can help people with advanced malignant pleural mesothelioma that hasn't responded to prior immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced malignant pleural mesothelioma that has not improved with prior immunotherapy.
- You have at least one tumor that can be safely injected with the study virus, and it is at least 1 cm on a CT scan.
- You are well enough to go about daily activities (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
This trial tests a new type of immune cell therapy made from donor cells that are trained to target two specific proteins found on mesothelioma tumors. The goal is to see if these cells can safely shrink tumors or slow the disease when given directly into the chest or belly area.
This trial studies a treatment plan that combines an immune drug (atezolizumab) and a personalized cancer vaccine (WT1/DC) with standard first-line chemotherapy for epithelioid malignant pleural mesothelioma that cannot be removed with surgery. It aims to improve control of the cancer by helping the immune system work alongside chemotherapy.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This trial tests whether adding cadonilimab (an immune treatment) and bevacizumab (a medicine that targets blood supply to tumors) to standard chemotherapy can control pleural malignant mesothelioma that cannot be removed with surgery. It’s meant for people who have not yet started medicine for advanced disease and who meet health and blood test requirements.
This Phase 2 study tests whether adding nivolumab (an immunotherapy) to a one-time “light-based” treatment during a lung procedure can control malignant pleural mesothelioma that can’t be surgically removed. You may be eligible if your cancer has come back or progressed after prior platinum chemotherapy, and if your tumor is reachable for the light treatment during thoracoscopy.
Hear when a new Malignant Pleural Mesothelioma, Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.